Response to comment on Have we been qualifying measurable residual disease correctly?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Response to comment on Have we been qualifying measurable residual disease correctly? ; volume:38 ; number:1 ; day:21 ; month:11 ; year:2023 ; pages:219-220 ; date:1.2024
Leukemia ; 38, Heft 1 (21.11.2023), 219-220, 1.2024
- Creator
-
Chen, Junren
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-023-02088-4
- URN
-
urn:nbn:de:101:1-2024032122144146681397
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Junren
- SpringerLink (Online service)
Other Objects (12)
Have we been qualifying measurable residual disease correctly?
Measurable residual disease
Measurable residual disease in multiple myeloma: ready for clinical practice?
Measurable residual disease (MRD)-testing in haematological and solid cancers
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
"Measurable distance"
Solidarity understood correctly
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Have we been qualifying measurable residual disease correctly?
Measurable residual disease
Measurable residual disease in multiple myeloma: ready for clinical practice?
Measurable residual disease (MRD)-testing in haematological and solid cancers
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
"Measurable distance"
Solidarity understood correctly
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Have we been qualifying measurable residual disease correctly?
Measurable residual disease
Measurable residual disease in multiple myeloma: ready for clinical practice?
Measurable residual disease (MRD)-testing in haematological and solid cancers
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
"Measurable distance"
Solidarity understood correctly
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia